Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1580 | Fruquintinib Wiki | 1.00 |
| drug927 | Clazakizumab Wiki | 0.41 |
Navigate: Correlations HPO
There is one clinical trial.
This is an open-label, multi-center, non-randomized, Phase 1b/2 study to assess the safety and efficacy of fruquintinib in combination with tislelizumab in patients with advanced, refractory TNBC. This study will be conducted in 2 parts; a safety lead-in phase (Part 1) and a dose expansion phase (Part 2). The safety lead-in phase will determine the RP2D. The RP2D will be administered to 2 cohorts of patients in the expansion phase. - Cohort A: TNBC (IO-treated) - Cohort B: TNBC (IO-Naïve)
Description: To assess the safety and tolerability by monitoring AEs characterized by type, frequency, severity per NCI-CTCAE v5.0
Measure: Adverse Events by type, frequency, and severity Time: At the end of Cycle 1 (each cycle is 28 days)Description: To confirm the RP2D of fruquintinib in combination with tislelizumab
Measure: Recommended Phase 2 Dose Time: At the end of Cycle 1 (each cycle is 28 days)Description: To evaluate the objective response rate (ORR) as assessed by the investigator in subjects with advanced TNBC when treated with fruquintinib in combination with tislelizumab
Measure: Objective Response Rate Time: Up to 1 yearAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports